SCIENCE
Long Covid research gets a big-time funding boost
NIH’s biggest initiative to research long Covid just got a huge cash infusion, the agency announced this week. Congress had given the initiative $1.15 billion to research the disease and how to treat it, and the new funding will give NIH another $515 million through 2028. That’s a nearly 50% budget increase.
I’ve written at length about how the initiative got off to a slow start, and how patients are concerned that it’s focused more on observing patients than actually testing treatments. Some senators in a recent hearing questioned whether money might be better spent through other agencies.
The patient advocates and experts I spoke with were cautiously optimistic — glad to see the cause getting more investment, but concerned about the short-term nature of the project and curious about exactly what the money will be spent on. Read more about the agency’s outline of where they plan to spend the money, and where it came from.
influence
An inside look at the *whole picture* of Washington lobbying
ALEX HOGAN/STAT
It’s an accepted fact among Washington insiders that big business’ efforts to lobby Congress go far beyond hiring professional lobbyists and cutting checks to politicians. But rarely are those lesser-known tactics – like paying think tanks for positive research and giving untraceable donations to so-called dark money groups – revealed publicly. Until now.
My colleague Nick Florko has been combing through 50,000 internal emails and documents from the e-cigarette company Juul. The documents show the lengths to which Juul went, at the height of the youth vaping crisis, to revamp its image and prevent both Congress and the FDA from taking action that could cost the company financially. The documents also reveal the vast network of organizations and well-connected politicos that were on the company’s payroll.
Take the prominent conservative think tank and advocacy group FreedomWorks. A signed contract between the group and Juul reveals that FreedomWorks charged the company $15,000 to generate comments to FDA regulatory dockets, and another $25,000 just to send emails to the organization’s membership about e-cigarettes.
As one advocate put it, Juul’s documents affirm “there are companies out there doing the things that advocates have been warning of.” To read more of Juul’s secrets, check out Nick’s story here.
oversight
Khan’t stop, won’t stop
Another drug sector dominated by a few middlemen is in the crosshairs of the Federal Trade Commission, my colleagues John Wilkerson and Ed Silverman report.
The FTC and HHS are looking into whether the organizations that hospitals and physicians use to buy drugs are contributing to shortages of cancer treatments and other injectable generic drugs. Those organizations are known as group purchasing organizations.
John attended the American Medical Association event at which FTC Chair Lina Khan announced the probe. The commission and HHS are jointly soliciting feedback on whether GPOs and drug wholesalers are in part behind drug shortages. Three group purchasing organizations buy about 90% of the drugs used by hospitals, and Khan worries that dominance might be distorting the market.
“When you have markets with outsized intermediaries that have dominant power, that gatekeeper role can create a whole set of problems,” Khan said.